Company: CDT
Filing Date: 2025-07-08
Form Type: DEF 14A
Source: 0001641172-25-018242
Chunk: 60

Company: CDT Equity Inc.
Filing Date: 2025-07-08
Form: DEF 14A
Chunk 60
---
 by operations, cash flow in excess of cost of capital, operating  
 margin, profit margin, contribution margin, stock price, new customers, order intake, cost         
 controls, operating efficiencies, strategic partnerships or transactions (including in-licensing   
 and out-licensing of intellectual property, milestones related to research development (including, 
 but not limited to, preclinical and clinical studies), product development and manufacturing,      
 implementation or completion of projects or processes (including, without limitation, clinical     
 trial initiation, clinical trial enrollment and dates, clinical trial results, regulatory          
 filing submissions, regulatory filing acceptances, regulatory or advisory committee interactions,  
 regulatory approvals, and product supply), submission to, or approval by, a regulatory body        
 (including, but not limited to the U.S. Food and Drug Administration) of an applicable filing      
 or a product, market penetration, geographic business expansion, cost targets, productivity,       
 corporate value and sustainability metrics (including, without limitation, environmental,          
 social and governance matters), human capital metrics (including, without limitation, employee     
 satisfaction, management of employment practices, employee benefits, retention and safety),        
 supervision of litigation or labor negotiations, dealings with regulatory bodies, acquisitions     
 or divestitures, customer satisfaction, strategic business criteria related to a participant’s     
 area or areas of responsibility, or other criteria established by the plan administrator.          |

Certain Transactions

In the event of any stock dividend or other distribution, stock split, reverse stock split, reorganization, combination or exchange of shares, merger, consolidation, split-up, spin-off, recapitalization, repurchase or any other corporate event affecting the number of outstanding shares of the Company common stock or the share price of the Company common stock that would require adjustments to the Amended 2023 Plan or any awards under the Amended 2023 Plan in order to prevent the dilution or enlargement of the potential benefits intended to be made available thereunder, the plan administrator will make appropriate, proportionate adjustments to: (i) the aggregate number and type of shares subject to the Amended 2023 Plan; (ii) the number and kind of shares subject to outstanding awards and terms and conditions of outstanding awards (including, without limitation, any applicable performance targets or criteria with respect to such awards); and (iii) the grant or exercise price per share of any outstanding awards under the Amended 2023 Plan; as well as granting new awards or making cash payments to participants. The administrator is also authorized to provide for the cancellation, exchange